JP2004534774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534774A5 JP2004534774A5 JP2002591503A JP2002591503A JP2004534774A5 JP 2004534774 A5 JP2004534774 A5 JP 2004534774A5 JP 2002591503 A JP2002591503 A JP 2002591503A JP 2002591503 A JP2002591503 A JP 2002591503A JP 2004534774 A5 JP2004534774 A5 JP 2004534774A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- optionally substituted
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 81
- 229910052736 halogen Inorganic materials 0.000 claims 44
- 150000002367 halogens Chemical class 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- -1 amino, carboxy Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003943 azolyl group Chemical group 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical group NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29307701P | 2001-05-23 | 2001-05-23 | |
| PCT/CA2002/000745 WO2002094830A2 (en) | 2001-05-23 | 2002-05-22 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534774A JP2004534774A (ja) | 2004-11-18 |
| JP2004534774A5 true JP2004534774A5 (enExample) | 2005-12-22 |
| JP4279561B2 JP4279561B2 (ja) | 2009-06-17 |
Family
ID=23127559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002591503A Expired - Fee Related JP4279561B2 (ja) | 2001-05-23 | 2002-05-22 | プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7144913B2 (enExample) |
| EP (1) | EP1395590B1 (enExample) |
| JP (1) | JP4279561B2 (enExample) |
| AT (1) | ATE340796T1 (enExample) |
| AU (1) | AU2002302248B2 (enExample) |
| CA (1) | CA2447779C (enExample) |
| DE (1) | DE60215000T2 (enExample) |
| ES (1) | ES2272712T3 (enExample) |
| WO (1) | WO2002094830A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1558614B1 (en) | 2002-10-30 | 2010-09-01 | Merck Frosst Canada Ltd. | Pyridopyrrolizine and pyridoindolizine derivatives |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| JP4051398B2 (ja) | 2004-03-11 | 2008-02-20 | アクテリオン ファマシューティカルズ リミテッド | テトラヒドロピリドインドール誘導体 |
| ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| US20070299122A1 (en) * | 2004-11-08 | 2007-12-27 | Tobert Jonathan A | Method of Treating Pathological Blushing |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| KR101329903B1 (ko) | 2004-12-27 | 2013-11-14 | 액테리온 파마슈티칼 리미티드 | Ｃｒｔｈ2 수용체 길항제로서의2,3,4,9-테트라하이드로-1ｈ-카르바졸유도체 |
| WO2006102079A1 (en) * | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| US7956082B2 (en) | 2005-07-22 | 2011-06-07 | Shionogi & Co., Ltd | Indole derivative having PGD2 receptor antagonist activity |
| EP1911759A4 (en) | 2005-07-22 | 2010-07-21 | Shionogi & Co | AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR |
| US7696222B2 (en) * | 2005-08-12 | 2010-04-13 | Merck Frosst Canada Ltd | Indole derivatives as CRTH2 receptor antagonists |
| JP5147401B2 (ja) | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| EP2316824A1 (en) | 2006-08-07 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates |
| US8772312B2 (en) * | 2007-10-10 | 2014-07-08 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Heterocyclic compounds as CRTH2 receptor antagonists |
| ES2471919T3 (es) | 2007-12-19 | 2014-06-27 | Amgen, Inc | Derivados de ácido fenilac�tico como moduladores de inflamación |
| EP2245002A4 (en) * | 2008-02-01 | 2011-08-17 | Amira Pharmaceuticals Inc | AMINOALKYLBIPHENYL ANTAGONISTS N, N 'DISUBSTITUTED FROM D2 RECEPTORS OF PROSTAGLANDIN |
| US8067445B2 (en) * | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| EP2257536A4 (en) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| US8426449B2 (en) * | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| US20110112134A1 (en) * | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
| EP2300425A4 (en) * | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS |
| MX2010014172A (es) | 2008-07-03 | 2011-02-22 | Amira Pharmaceuticals Inc | Antagonistas de receptores de prostaglandina d2. |
| WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) * | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| US20100173313A1 (en) * | 2009-01-08 | 2010-07-08 | Amira Pharmaceuticals, Inc. | Biomarkers of inflammation |
| WO2011014587A2 (en) | 2009-07-31 | 2011-02-03 | Amira Pharmaceuticals, Inc. | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| KR20120047273A (ko) * | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 길항제 및 이의 용도 |
| WO2011035417A1 (en) * | 2009-09-25 | 2011-03-31 | Aegera Therapeutics Inc. | Hsp-90 binding compounds, compositions thereof, and their use fn the treatment of autoimmune and inflammatory diseases |
| MX2012007927A (es) | 2010-01-06 | 2012-08-15 | Panmira Pharmaceuticals Llc | Antagonistas de dp2 y usos del mismo. |
| MX2012010820A (es) | 2010-03-22 | 2012-10-10 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2. |
| CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| PL2606032T3 (pl) * | 2010-08-20 | 2015-07-31 | Univ Washington Through Its Center For Commercialization | Kompozycja i sposoby terapii glejakaep |
| KR101927556B1 (ko) * | 2011-03-02 | 2018-12-10 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 아릴- 및 헤테로아릴아세트산 유도체의 제조 방법 |
| WO2012126084A1 (en) * | 2011-03-24 | 2012-09-27 | Pharmascience Inc. | Hsp-90 binding compounds, compositions thereof, and their use iν the treatment and prevention of fungal infections |
| WO2012140612A1 (en) | 2011-04-14 | 2012-10-18 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| TW201331179A (zh) | 2011-12-21 | 2013-08-01 | Actelion Pharmaceuticals Ltd | 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途 |
| EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| EP2912458B1 (en) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| PH12016501764B1 (en) | 2014-03-17 | 2024-05-17 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| JP6770522B2 (ja) | 2015-02-13 | 2020-10-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017046125A1 (en) | 2015-09-15 | 2017-03-23 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| US11524958B2 (en) * | 2016-07-21 | 2022-12-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound as CRTH2 inhibitor |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| WO2021113710A1 (en) | 2019-12-04 | 2021-06-10 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1241660A (en) * | 1984-06-25 | 1988-09-06 | Yvan Guindon | Indole-2-alkanoic acids |
| EE200000522A (et) * | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
-
2002
- 2002-05-22 DE DE60215000T patent/DE60215000T2/de not_active Expired - Lifetime
- 2002-05-22 WO PCT/CA2002/000745 patent/WO2002094830A2/en not_active Ceased
- 2002-05-22 AU AU2002302248A patent/AU2002302248B2/en not_active Ceased
- 2002-05-22 CA CA2447779A patent/CA2447779C/en not_active Expired - Fee Related
- 2002-05-22 EP EP02729708A patent/EP1395590B1/en not_active Expired - Lifetime
- 2002-05-22 AT AT02729708T patent/ATE340796T1/de not_active IP Right Cessation
- 2002-05-22 ES ES02729708T patent/ES2272712T3/es not_active Expired - Lifetime
- 2002-05-22 JP JP2002591503A patent/JP4279561B2/ja not_active Expired - Fee Related
- 2002-05-22 US US10/474,929 patent/US7144913B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543976A5 (enExample) | ||
| RU2005116254A (ru) | Производные пиридопирролизина и пиридоиндолизина | |
| JP2023052094A5 (enExample) | ||
| CA2189830C (en) | Uses for corticotropin releasing factor atagonists | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2022545359A5 (enExample) | ||
| CA2443950A1 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| JP2013545791A5 (enExample) | ||
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| HRP20161306T1 (hr) | Dimerni spojevi kao agonisti receptora fgf (fgfr), postupak za njihovu pripravu i njihova terapijska uporaba | |
| JP2004516314A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| JP2016510785A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2006132071A (ru) | Производные антраниловой кислоты, способы их получения и применение | |
| JP2004525174A5 (enExample) | ||
| SI9620136B (en) | Substituted n-/(aminoiminomethyl or aminomethyl)phenyl/-propyl amides | |
| JP2001526218A5 (enExample) | ||
| JP2023538524A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| JP2024507414A5 (enExample) | ||
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| JP2007532607A5 (enExample) |